• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

胶质母细胞瘤患者中致癌变异作为预后因素的系统评价和荟萃分析

oncogenic variants as prognostic factors in individuals with glioblastoma: a systematic review and meta-analysis.

作者信息

Esperante Diego, Galicia Kena Daza, Rivas-Cuervo Kalu Gabriel, Cacho-Díaz Bernardo, Trejo-Becerril Catalina, Taja-Chayeb Lucia, Aboud Orwa, Carlos-Escalante José Alberto, Wegman-Ostrosky Talia

机构信息

Combined Studies Plan in Medicine (PECEM), Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico.

Faculty of Medicine, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico.

出版信息

Front Neurol. 2024 Dec 18;15:1490246. doi: 10.3389/fneur.2024.1490246. eCollection 2024.

DOI:10.3389/fneur.2024.1490246
PMID:39744115
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11688405/
Abstract

BACKGROUND

This systematic review and meta-analysis investigated the relationship between somatic oncogenic variants and prognosis, specifically with overall survival (OS) and progression-free survival (PFS) in patients diagnosed with supratentorial glioblastoma.

METHODS

We included longitudinal studies and clinical trials involving a minimum of 40 adult participants diagnosed with supratentorial glioblastoma, wherein the status of variants was assessed. We conducted searches in multiple databases. We assessed bias risk using a modified version of the Quality in Prognosis Studies tool, and the certainty of evidence was evaluated following the principles of the GRADE approach.

RESULTS AND CONCLUSION

This study encompassed 23 papers involving 2,555 patients, out of which 716 had reported oncogenic variants. oncogenic variants were associated with a reduced likelihood of 1-year survival (OR 0.52, 95% CI 0.29-0.94). However, our analysis did not reveal any significant impact of variants on overall survival, progression-free survival, or 2-year survival. Therefore, this comprehensive analysis demonstrates that the presence of genetic variants in does not provide useful information for the prognosis of glioblastoma.

SYSTEMATIC REVIEW REGISTRATION

https://www.crd.york.ac.uk/prospero/, identifier CRD42021289496.

摘要

背景

本系统评价和荟萃分析研究了体细胞致癌变异与预后之间的关系，特别是与幕上胶质母细胞瘤患者的总生存期（OS）和无进展生存期（PFS）的关系。

方法

我们纳入了涉及至少40名诊断为幕上胶质母细胞瘤的成年参与者的纵向研究和临床试验，其中评估了变异状态。我们在多个数据库中进行了检索。我们使用改良版的预后研究质量工具评估偏倚风险，并按照GRADE方法的原则评估证据的确定性。

结果与结论

本研究纳入了23篇论文，涉及2555名患者，其中716名报告了致癌变异。致癌变异与1年生存率降低相关（OR 0.52，95%CI 0.29 - 0.94）。然而，我们的分析未发现变异对总生存期、无进展生存期或2年生存率有任何显著影响。因此，这项综合分析表明，胶质母细胞瘤中遗传变异的存在并不能为其预后提供有用信息。

系统评价注册

https://www.crd.york.ac.uk/prospero/，标识符CRD42021289496。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/579a/11688405/837517e42abe/fneur-15-1490246-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/579a/11688405/095b4da3ae4d/fneur-15-1490246-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/579a/11688405/e98eec0bf1ed/fneur-15-1490246-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/579a/11688405/a35b7cf869a7/fneur-15-1490246-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/579a/11688405/f4febe665428/fneur-15-1490246-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/579a/11688405/90925883ada9/fneur-15-1490246-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/579a/11688405/837517e42abe/fneur-15-1490246-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/579a/11688405/095b4da3ae4d/fneur-15-1490246-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/579a/11688405/e98eec0bf1ed/fneur-15-1490246-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/579a/11688405/a35b7cf869a7/fneur-15-1490246-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/579a/11688405/f4febe665428/fneur-15-1490246-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/579a/11688405/90925883ada9/fneur-15-1490246-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/579a/11688405/837517e42abe/fneur-15-1490246-g006.jpg

相似文献

1
oncogenic variants as prognostic factors in individuals with glioblastoma: a systematic review and meta-analysis.胶质母细胞瘤患者中致癌变异作为预后因素的系统评价和荟萃分析
Front Neurol. 2024 Dec 18;15:1490246. doi: 10.3389/fneur.2024.1490246. eCollection 2024.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区，服用抗叶酸抗疟药物的人群中，叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.成人霍奇金淋巴瘤预后的中期PET结果：一项预后因素研究的系统评价和荟萃分析
Cochrane Database Syst Rev. 2019 Sep 16;9(9):CD012643. doi: 10.1002/14651858.CD012643.pub2.
4
Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.成人霍奇金淋巴瘤预后的中期PET结果：预后因素研究的系统评价和荟萃分析
Cochrane Database Syst Rev. 2020 Jan 13;1(1):CD012643. doi: 10.1002/14651858.CD012643.pub3.
5
Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.治疗胶质母细胞瘤进展或复发的选择：网络荟萃分析。
Cochrane Database Syst Rev. 2021 May 4;5(1):CD013579. doi: 10.1002/14651858.CD013579.pub2.
6
Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.成人新诊断慢性淋巴细胞白血病的预后模型：一项系统评价和荟萃分析。
Cochrane Database Syst Rev. 2020 Jul 31;7(7):CD012022. doi: 10.1002/14651858.CD012022.pub2.
7
Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis.老年新诊断胶质母细胞瘤的治疗：一项网状Meta分析
Cochrane Database Syst Rev. 2020 Mar 23;3(3):CD013261. doi: 10.1002/14651858.CD013261.pub2.
8
Anti-angiogenic therapy for high-grade glioma.高级别胶质瘤的抗血管生成治疗。
Cochrane Database Syst Rev. 2018 Nov 22;11(11):CD008218. doi: 10.1002/14651858.CD008218.pub4.
9
Prognostic value of inflammatory markers NLR, PLR, and LMR in gastric cancer patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review.免疫检查点抑制剂治疗胃癌患者中炎症标志物 NLR、PLR 和 LMR 的预后价值：荟萃分析和系统评价。
Front Immunol. 2024 Jul 10;15:1408700. doi: 10.3389/fimmu.2024.1408700. eCollection 2024.
10
Germline rare variants in HER2-positive breast cancer predisposition: a systematic review and meta-analysis.HER2阳性乳腺癌易感性中的种系罕见变异：一项系统综述和荟萃分析。
Front Oncol. 2024 Jun 24;14:1395970. doi: 10.3389/fonc.2024.1395970. eCollection 2024.

引用本文的文献

1
Diagnostic Utility of Intratumoral Susceptibility Signals in Adult Diffuse Gliomas: Tumor Grade Prediction and Correlation with Molecular Markers Within the WHO CNS5 (2021) Classification.成人弥漫性胶质瘤瘤内易感性信号的诊断效用：肿瘤分级预测及与世界卫生组织中枢神经系统肿瘤分类第5版（2021年）中分子标志物的相关性
J Clin Med. 2025 Jun 5;14(11):4004. doi: 10.3390/jcm14114004.

本文引用的文献

1
MDM2 Inhibition in the Treatment of Glioblastoma: From Concept to Clinical Investigation.MDM2抑制在胶质母细胞瘤治疗中的应用：从概念到临床研究
Biomedicines. 2023 Jul 2;11(7):1879. doi: 10.3390/biomedicines11071879.
2
Targeting Biomolecular Condensation and Protein Aggregation against Cancer.靶向生物分子凝聚和蛋白质聚集治疗癌症。
Chem Rev. 2023 Jul 26;123(14):9094-9138. doi: 10.1021/acs.chemrev.3c00131. Epub 2023 Jun 28.
3
Targeting p53 pathways: mechanisms, structures, and advances in therapy.靶向 p53 通路：机制、结构和治疗进展。
Signal Transduct Target Ther. 2023 Mar 1;8(1):92. doi: 10.1038/s41392-023-01347-1.
4
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019.美国 2015-2019 年确诊的原发性脑和其他中枢神经系统肿瘤 CBTRUS 统计报告。
Neuro Oncol. 2022 Oct 5;24(Suppl 5):v1-v95. doi: 10.1093/neuonc/noac202.
5
Molecular alterations associated with improved outcome in patients with glioblastoma treated with Tumor-Treating Fields.与接受肿瘤治疗电场治疗的胶质母细胞瘤患者预后改善相关的分子改变
Neurooncol Adv. 2022 Jun 21;4(1):vdac096. doi: 10.1093/noajnl/vdac096. eCollection 2022 Jan-Dec.
6
Multivariate analysis of associations between clinical sequencing and outcome in glioblastoma.胶质母细胞瘤临床测序与预后之间关联的多变量分析。
Neurooncol Adv. 2022 Jan 10;4(1):vdac002. doi: 10.1093/noajnl/vdac002. eCollection 2022 Jan-Dec.
7
Clinical and survival characteristics of primary and secondary gliosarcoma patients.原发性和继发性胶质肉瘤患者的临床及生存特征
Clin Neurol Neurosurg. 2022 Mar;214:107146. doi: 10.1016/j.clineuro.2022.107146. Epub 2022 Jan 29.
8
Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC).癌症体细胞变异致病性分类标准（致癌性）：临床基因组资源（ClinGen）、癌症基因组联盟（CGC）和癌症变异解读联盟（VICC）的联合建议。
Genet Med. 2022 May;24(5):986-998. doi: 10.1016/j.gim.2022.01.001. Epub 2022 Jan 29.
9
Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study.携致病性或疑似致病性种系 TP53 变异个体的癌症发病情况、模式及基因型-表型相关性：一项观察性队列研究。
Lancet Oncol. 2021 Dec;22(12):1787-1798. doi: 10.1016/S1470-2045(21)00580-5. Epub 2021 Nov 12.
10
Mutation Is a Prognostic Factor in Lower Grade Glioma and May Influence Chemotherapy Efficacy.突变是低级别胶质瘤的一个预后因素，且可能影响化疗疗效。
Cancers (Basel). 2021 Oct 26;13(21):5362. doi: 10.3390/cancers13215362.